Our findings suggest that the assessment of rearrangements involving PLAG1 or HMGA2 in breast PAs, and of MAML2 rearrangements in breast MECs, might be used as ancillary tools to aid in the diagnosis of these rare breast tumors. Here, MAML2 is linked to breast neoplasm.